A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer
Latest Information Update: 21 Sep 2024
At a glance
- Drugs Fosifloxuridine nafalbenamide (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Levofolinic acid
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms NuTide 323
- Sponsors NuCana
Most Recent Events
- 02 Sep 2024 Status changed from active, no longer recruiting to discontinued.
- 29 Aug 2024 According to a NuCana media release, the study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan and bevacizumab (NUFIRI+bev) was unlikely to achieve the study's primary objective of superior Progression Free Survival (PFS) compared to the control arm.
- 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.